Clinical

According to a news report in Nature, scientists at Sichuan University’s West China Hospital are on track to initiate a clinical trial that will administer CRISPR-Cas9—edited immune cells in patients diagnosed with lung cancer.

A letter published in The New England Journal of Medicine provides narrative of a clinical interference that has been documented with the much hailed multiple myeloma drug daratumumab.

Data from the phase 3 METEOR trial presented at the 2016 annual meeting of the American Society of Clinical Oncology showed that cabozantinib reduced the risk of death in patients with advanced renal cell carcinoma by 34%, compared with everolimus.

A proof-of-concept study in ovarian cancer shows advantage of using liquid biopsy for the earlier detection of disease relapse.

On an earnings call yesterday, Novartis announced that the FDA has sent a complete response letter for their product pegfilgrastim, biosimilar to Neulesta.

During a health policy session at the annual meeting of the American Society of Clinical Oncology, Steven J. Katz, MD, MPH, discussed the Oncotype DX Breast Cancer Assay, and it's impact on recommendations for chemotherapy in early-stage breast cancer.

A long-term follow up study among Dutch women who underwent in-vitro fertilization (IVF) treatment in the Netherlands has failed to find an association between the treatment and an increased risk of breast cancer.

Research from The University of Texas MD Anderson Cancer Center has tried to fill the knowledge gaps that exist in the treatment of colorectal cancers that harbor mutations in genes involved in DNA mismatch repair.